Healthcare Providers and Services
Company Overview of Boston Heart Diagnostics Corporation
Boston Heart Diagnostics Corporation provides heart diagnostic services in the United States. The company offers personalized diagnostics and reports, and customized nutrition and lifestyle programs for healthcare providers and their patients. It offers Boston Heart HDL Map, a test that quantifies the amount of apoA-I in the five most significant subpopulations, resulting in an understanding of a patient’s cardiovascular disease (CVD) risk; Boston Heart Cholesterol Balance Test, a test that directly measures the production and absorption markers for circulating plasma cholesterol; Boston Heart Statin Induced Myopathy (SLCO1B1) Genotype test that identifies those patients who are at higher ri...
175 Crossing Boulevard
Framingham, MA 01702
Founded in 2007
Key Executives for Boston Heart Diagnostics Corporation
Co-Founder, Chief Medical Officer, Director and Member of Scientific Advisory Board
Co-Founder, Chief Scientific Officer and Member of Scientific Advisory Board
Senior Vice President of Clinical Diagnostics for Us-East Eurofins
Compensation as of Fiscal Year 2017.
Boston Heart Diagnostics Corporation Key Developments
Boston Heart Diagnostics Corporation Appoints Pat Noland as President
May 25 17
Boston Heart Diagnostics announce the appointment of Pat Noland as President effective April 2017. Pat brings a wealth of leadership experience in laboratory sciences,
and he has proven success in developing and executing strategies for revenue and earnings growth as well as in leadership, communication, and organizational development. For the past 25 years, Pat has worked for various companies such as Laboratory Corporation of America (LabCorp), StrataDx- Strata Pathology Services Inc., and Genetic Signatures Limited, in a number of leadership roles. Pat has most recently been working as a US Market Consultant at Genetic Signatures Limited since July 2016— previously serving as Executive Vice President of US Operations.
Boston Heart Announces the Launch of Life Plan 2.0
Jan 20 16
Boston Heart announced the launch of Life Plan 2.0, the next generation of its scientifically-designed nutrition and lifestyle plan that helps patients achieve their weight management goal and their overall heart health. This easy to understand plan provides patients at risk for cardiovascular disease with a strategy to help them take control of their heart health. Grounded in science, Life Plan 2.0 takes Boston Heart’s Nutrition and Lifestyle Program to the next level by providing a truly individualized plan for each unique patient. The plan features customized weight and fitness goals and specific recommendations to improve biomarker test results and to reduce heart disease risk.
Boston Heart Diagnostics Introduces StatinSmart
Nov 19 15
Boston Heart Diagnostics announced the launch of StatinSmart, the first and only at-home saliva laboratory developed test that analyzes the SLCO1B1 (Solute Carrier Organic Anion Transporter 1B1) gene for a variant known to increase an individual’s risk for developing statin induced myopathy - the onset of muscle aches, spasms and pain associated with statin therapy. StatinSmart helps patients understand how their bodies will process a statin and encourages them to discuss with their healthcare provider the type of statin that is best suited to their genotype. With this information, patients can work with their healthcare provider to personalize a plan to lower cholesterol without unnecessary side effects.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries